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Abstract p23 is a regulatory co-chaperone of heat shock pro-
tein (Hsp) 90, but can also act as a general molecular chaperone
by itself. Using novel point mutations of p23 that disrupt its
interaction with Hsp90 we found its co-chaperone function to
be required for its inhibitory e¡ect on glucocorticoid receptor
(GR). The C-terminal region of p23, which is required for its
chaperone activity, is dispensable for inhibition of GR. Impor-
tantly, similar results were obtained with a constitutively active
GR. Thus, the action of p23 on the nuclear stage of GR regu-
lation requires its Hsp90 co-chaperone function, but not its
chaperone activity.
* 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Molecular chaperones promote the correct folding of pro-
teins to their native state [1,2]. Heat shock protein (Hsp) 90 is
a highly conserved ubiquitous protein that functions as a cen-
tral folding platform for diverse proteins including steroid
receptors such as the glucocorticoid receptor (GR) [3^5].
Hsp90 acts together with Hsp70, p23 and various other pro-
tein cofactors to fold and stabilize the ligand binding domain
of GR [4].
p23 interacts with Hsp90 as a regulatory cofactor and binds
to the adenosine triphosphate (ATP)-bound form of Hsp90
[6^8]. Geldanamycin disrupts the Hsp90^p23 interaction
[9,10]. It has been reported that human p23 reduces the ATP-
ase activity of Hsp90 [11] and enhances the Hsp90-mediated
folding of GR in vitro [12] and in vivo [13]. Upon hydrolysis
of ATP by Hsp90, p23 also enhances dissociation of substrate
from Hsp90 [14]. In mammalian and yeast cells, increased
expression of p23 raised the ligand e⁄ciency of GR by acting
through its ligand binding domain [15].
In addition to its regulation of Hsp90, p23 acts as molec-
ular chaperone itself and prevents protein aggregation [16,17].
The unstructured C-terminal region of p23 is necessary for its
chaperone function [18], but this region is not required for
interaction with Hsp90 or its regulatory co-chaperone func-
tion [14,19]. The crystal structure of a p23 lacking the C-ter-
minal chaperone domain revealed a cluster of conserved res-
idues on one face of the protein, possibly providing a binding
face for Hsp90 [19].
More recently, p23 was found to act not only in the acti-
vation of GR [12], but also in its inhibition by disassembling
transcriptional regulatory complexes of the receptor [20]. The
transcriptional activity of GR in vivo was reduced by chro-
matin-targeted or intact p23. Moreover, p23 reduced the oc-
cupancy of glucocorticoid response elements by GR. Chroma-
tin-targeted Hsp90 displayed similar e¡ects on transcription
complexes [20]. These observations give rise to the crucial
question of whether the e¡ects of p23 on transcriptional ac-
tivity are due to its intrinsic chaperone activity, or its role as
an Hsp90 co-chaperone.
We addressed this question by examining the in vivo inhi-
bition of GR activity by p23. Using novel point mutants of
p23 unable to bind Hsp90, we demonstrate that the co-chap-
erone function of p23 is required for its inhibition of GR. In
contrast, the C-terminal region of p23 necessary for its intrin-
sic chaperone activity is not involved in GR inhibition. Im-
portantly, p23 also inhibited the transcriptional activity of a
GR devoid of the ligand binding domain in an Hsp90-depen-
dent manner.
2. Materials and methods
2.1. Cell culture, transfection, luciferase and L-galactosidase assay
Cell cultivation and transfection were as described [21]. Unless oth-
erwise indicated, amounts of transfected plasmids perV107 cells were
1.5 Wg steroid-responsive luciferase reporter plasmid MTVLuc, 2 Wg
L-galactosidase vector pCMVL-Gal (Stratagene) as control, p23 ex-
pression plasmid as indicated and 0.75 Wg pRK7GR that expresses
human GR, or a FLAG-tagged version. The total amount of plasmids
was kept constant for each condition by supplementing expression
vector.
Luciferase and L-galactosidase assays were as described [21]. Unless
described otherwise, luciferase data are presented as percent of stim-
ulation. That is, after normalization of the data to galactosidase ac-
tivities, fold stimulation of luciferase expression was calculated by
comparing cells without to cells with hormone. The stimulation in
the absence of cotransfected p23 was set to 100%. For the hor-
mone-independent GR stimulation was calculated by comparing cells
in the presence versus absence of cotransfected GR.
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2.2. Plasmids
The plasmids MTVLuc have been described [21], pRK7GR1-515,
pRK7GR were recloned by A. Ho¡mann with an N-terminal HA-tag
from cDNAs originally obtained from R. Evans. The green £uores-
cence protein (GFP)-tagged truncated GR was cloned into pEGFPC1
(Clontech).
For expression of p23 variants, the respective cDNAs were inserted
in the vector pRK5MCS, and clones were veri¢ed by sequencing.
Details are available on request.
2.3. Immunoprecipitation and immunoblots
For immunoprecipitation, a FLAG-tagged form of the protein of
interest was expressed in human embryonic kidney (HEK) cells. Cells
were solubilized in 1 ml lysis bu¡er (20 mM Tris/HCl pH 7.5; 130
mM NaCl; 20 mM Na2MoO4 ; 1 mM ethylenediamine tetraacetic acid
(EDTA); 10% glycerol; 0.5% Triton X-100; 1:100 protease inhibitor
cocktail, Sigma). The extract was incubated for 1 h on ice, centrifuged
for 4 min at 13 000 rpm and protein concentration was determined
(BCA kit; Pierce). Lysates were incubated with an anti-FLAG M2
a⁄nity gel overnight at 4‡C. Beads were washed three times with
1UTris-bu¡ered saline and samples were eluted with sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) sample bu¡-
er without reducing agent.
For immunoblot detection either 15 Wg of total protein from the cell
extracts used to determine luciferase activity or immunoprecipitates
were separated by SDS^PAGE and transferred to nitrocellulose mem-
brane (SchleicherpSchu« ll GmbH, Germany). Hsp90 was detected with
rabbit polyclonal antibody (H-114, Santa Cruz), p23 with a mouse
monoclonal antibody (ABR), FLAG-tagged proteins with a monoclo-
nal anti-FLAG antibody (M2, Sigma), and HA-tagged GRs with a
monoclonal anti-HA antibody (Roche, Germany). When two proteins
were identi¢ed consecutively on the same blot, stripping bu¡er
(Pierce) was used after detection of the ¢rst protein. Signals were
visualized with appropriate secondary antibodies and the enhanced
chemiluminescence (ECL) system and autoradiography.
2.4. Fluorescence detection
HeLa cells were seeded on gelatin-coated glass plates in a six-well
plate and transfected with ExGen (Fermentas) as recommended by
the manufacturer. 0.25 Wg GFP-truncated receptor plasmid were used
per well. After 24 h, cells were ¢xed with 4% paraformaldehyde (PFA)
for 20 min, washed two times (1UTTBS, 5% fetal calf serum (FCS),
1% bovine serum albumin (BSA), 1% Triton X-100) and then em-
bedded in ‘ProTaqs Mount Fluor’ (Biocyc GmbH and CoKG, Ger-
many). The microscope was ‘Axioplan 2 imaging’ (Zeiss, Jena, Ger-
many).
3. Results
3.1. p23 inhibits GR activity in a dose-dependent manner
To investigate the e¡ect of p23 on GR activity, we devel-
oped an assay with a GR-dependent luciferase reporter gene
in neuroblastoma cells. p23 decreased the transcriptional ac-
tivity of GR in a dose-dependent manner in SK-N-MC cells
(Fig. 1A). This decrease was not due to degradation of the
receptor (Fig. 1B). Similar results were obtained in HEK,
COS1 and HeLa cells (unpublished), strongly suggesting
that the observed inhibition is not cell type-speci¢c. FLAG-
tagged and untagged p23 produced identical results (unpub-
lished). The inhibition of GR by p23 was at least partially
overcome by increasing concentrations of hormone (inset
Fig. 1A). Western blotting revealed a moderate increase of
total p23 levels under our assay conditions (Fig. 1C). We
also tested whether overexpression of p23 leads to disruption
of the Hsp90^GR complex in the cytosol, since this could
explain the inhibitory activity of p23. We precipitated
FLAG-tagged GR in the presence or absence of cotransfected
p23 and found no di¡erence in the amount of coprecipitated
Hsp90 (Fig. 1D). Cells not expressing FLAG-tagged GR pro-
duced no background (unpublished).
3.2. Two hydrophobic residues on the surface of p23 are
required for binding to Hsp90
The goal of this study was to determine whether the Hsp90
co-chaperone function of p23 or its intrinsic chaperone func-
tion is required for GR inhibition. To target its chaperone
function, we deleted the C-terminus of p23, which removes
its chaperone activity [18], but leaves Hsp90 binding and co-
chaperone function intact [14,19]. We veri¢ed that p23 lacking
the C-terminal 35 amino acids indeed interacted with Hsp90
(C35, Fig. 2B). To target the Hsp90 co-chaperone function,
we established mutants that could not bind Hsp90. Important
clues were provided by the crystal structure [19] and the iden-
ti¢cation of conserved amino acids in p23 (Fig. 2A). There are
conserved residues mainly within the ¢rst 108 amino acids
with stronger conservation between residues 86 and 108. We
mutated the hydrophobic amino acids phenylalanine (position
103) and tryptophan (106) to alanines (F103A/W106A,
‘ANNA’ Fig. 2A). These two conserved bulky aromatic ami-
no acids are exposed on the surface of the protein [19]. There-
fore, they are not contributing to maintain p23 structure, but
likely to be involved in recognizing Hsp90. Mutation of these
two amino acids indeed abolished binding to Hsp90 (Fig. 2B).
Fig. 1. p23 inhibits GR-dependent transcription. SK-N-MC were
transfected with a reporter plasmid, a GR expressing plasmid, a
L-galactosidase plasmid, increasing amounts of p23 expression plas-
mid as indicated, and cultivated for 16 h in the presence of 10 nM
cortisol. A: Luciferase activities, calculated as percent of stimula-
tion. Data represent four independent experiments performed in du-
plicate. Inset: E¡ect of p23 (1 Wg plasmid) at di¡erent concentra-
tions of cortisol. B: Representative Western blot of the HA-tagged
GR. C: Western blot comparing endogenous levels of p23 with total
levels of p23 after transfection. D: HEK cells were transfected with
FLAG-tagged GR and p23 expressing plasmids, as indicated,
FLAG-tagged GR was precipitated from lysates (upper panel) and
was determined on the same blot after detecting coprecipitated
Hsp90 (lower panel).
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Also, the single point mutations F103A and W106A disrupted
interaction with Hsp90 (Fig. 2B).
3.3. Hsp90 binding of p23, but not its C-terminal chaperone
domain, is required for its inhibitory e¡ect on GR
The mutants described above were tested in our reporter
assay. The ANNA (F103A/W106A), F103A and W106A
p23 mutants that were unable to bind Hsp90 were also unable
to inhibit transcriptional activity of GR (Fig. 2C). To evaluate
the contribution of the intrinsic p23 chaperone activity, we
tested the e¡ect of the C-terminal deletion mutant. Deletion
of the 30 or 35 C-terminal amino acids of p23 severely impairs
the intrinsic chaperone activity of the protein [18,19]. The C35
deletion mutant was as e¡ective as wild-type p23 in the inhi-
bition of GR activity (Fig. 2C). Therefore, the Hsp90-depen-
dent co-chaperone function of p23 is required for its e¡ect on
GR, but not its intrinsic chaperone activity.
3.4. p23 also a¡ects a constitutively nuclear GR in an
Hsp90-dependent manner
p23 has been implicated in the folding reactions of steroid
receptors [22], which take place in the cytosolic compartment
of the cell, and in late nuclear steps of receptor activation [15],
i.e. in disassembly of transcriptional regulatory complexes
[20]. Using GFP-tagged p23 we found that p23 is evenly dis-
tributed in both the cytosol and the nucleus (unpublished).
Therefore, the inhibition of GR by p23 could be due to an
action in either one or both subcellular compartments.
To determine if p23 acts on transcriptionally active GR in
the nucleus, we tested a truncated, constitutively active GR
(amino acids 1^515), which activates transcription indepen-
dently of hormone [23]. This GR was also inhibited by p23
in an Hsp90-dependent manner (Fig. 3A), because the ANNA
(F103A/W106A) mutant was inactive. In contrast, the C-ter-
minal truncation of p23 did not abolish the inhibitory e¡ect
on this GR (Fig. 3A). There was no degradation of the trun-
cated GR (Fig. 3B). We also veri¢ed that the truncated GR is
exclusively nuclear, as predicted (Fig. 3C). The relative inhi-
bition of the hormone-independent GR seems lower when
compared to full-length GR. This may be explained by the
already reduced transcriptional activity of the truncated GR.
Alternatively, the higher expression levels of the truncated GR
may require also higher levels of p23 for comparable inhibi-
tion.
Fig. 2. Hsp90 interaction of p23 is required for its inhibitory e¡ect
on GR, but not its C-terminal region. A: Structure of wild-type p23
and mutants. Light gray, region of highest conservation; bold let-
ters, conserved amino acids [19]; dark gray, unstructured C-termi-
nus required for chaperone activity [18,19]. B: Immunoprecipitation
of FLAG-tagged wild-type p23 and mutants. Upper panel: Western
blot with anti-FLAG antibody to control input of precipitation.
Lower panel: Western blot of the immunoprecipitation with an
Hsp90 antibody. C: SK-N-MC cells were transfected with the re-
porter plasmid, the GR plasmid, L-galactosidase plasmid, and 3 Wg
of either control vector (c), wild-type, or mutated p23, respectively.
Data represent four independent experiments performed in dupli-
cate.
Fig. 3. p23 inhibits a constitutively active GR in an Hsp90-depen-
dent manner. A: SK-N-MC cells were transfected with the reporter
plasmid, 1 Wg of a plasmid expressing a truncated GR, L-galactosi-
dase plasmid and 3 Wg of control vector (c) or respective p23 plas-
mid, and cultivated for 16 h. Data represent 15 independent experi-
ments for wild-type p23, 14 for ANNA and eight for C35
performed in duplicate. B: Representative Western blot of the HA-
tagged truncated GR. C: Representative £uorescence picture of
GFP-tagged truncated GR in HeLa cells.
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4. Discussion
p23 can act biochemically as co-chaperone by interacting
with Hsp90, and as chaperone by binding to unfolded poly-
peptides. Here, we elucidate for the ¢rst time the contribu-
tions of these two biochemical activities to the function of p23
in vivo. In the negative regulation of GR transcriptional acti-
vation, p23 apparently functions through its interaction with
Hsp90 rather than through its chaperone activity.
Although the p23^Hsp90 interaction was indispensable for
inhibiting GR (Figs. 2 and 3), a C-terminal deletion mutant
impairing the chaperone activity of p23 [18,19] was as e¡ective
as wild-type p23. Similar C-terminal deletions in p23 also did
not a¡ect the activity of p23 in the ATP-dependent substrate
release from Hsp90 [14]. Together, these data suggest that the
Hsp90 regulatory and chaperone activities of p23 operate in-
dependently of each other. The chaperone function of p23 has
not been linked to a speci¢c process in vivo, but may be
relevant in stress conditions.
As part of our study we established point mutants of p23
that disrupt binding to Hsp90. Mutation of conserved bulky
hydrophobic residues exposed on the surface of p23 is su⁄-
cient to disrupt its Hsp90 binding (Fig. 2). Very recently,
other contact points of p23 with Hsp90 have also been re-
ported [24], and the combined results outline an interaction
surface that spans the conserved core of p23.
p23 inhibited the activity of both full-length GR and GR
lacking the ligand binding domain, apparently through similar
Hsp90-dependent mechanisms. Hsp90 together with p23 may
act either on co-regulators recruited by GR, or directly on GR
itself. For the truncated GR, the latter explanation seems
unlikely, as the ligand binding domain of GR is thought to
be the Hsp90 interaction site [25]. Nevertheless, a second,
possibly weaker or transient interaction site of GR with
Hsp90 cannot be excluded. Many cofactors are recruited by
the N-terminus of GR [26], which may be targets of Hsp90.
An earlier study reported enhancement of rat GR activity
by p23 while other steroid receptors like rat mineralocorticoid
receptor or human estrogen receptor were inhibited [15]. The
reason for the seeming discrepancy to our study is unknown,
but may lay in di¡erences of experimental settings, e.g. rat
GR versus human GR. We observed inhibition of GR by
p23 in four di¡erent cell lines and already at relatively low
doses of p23 (Fig. 1). Importantly, our p23 expression con-
ditions did not lead to disruption of the Hsp90 heterocom-
plex. Our results support and extend a more recent report that
describes disassembly of transcriptional complexes and inhibi-
tion of GR activity by both chromatin-targeted and intact p23
[20], as well as chromatin-targeted Hsp90. Based on their
model, our results suggest that Hsp90 and p23 work together
in disassembling transcriptionally active GR from chromatin.
In principle, increased p23 expression could act on both the
cytosolic and the nuclear Hsp90-regulated processes. By using
the hormone-independent GR (Fig. 3), we have now analyzed
speci¢cally the nuclear function of p23, and shown that this
involves Hsp90 interaction.
p23-mediated inhibition of a steroid receptor-independent
promoter has been reported [20]. However, Hsp90 and p23
are not general transcription inhibitors: we found that the
receptor-independent transcription from the MMTV pro-
moter and the CMV promoter-driven transcription were un-
a¡ected (unpublished). It will be interesting to learn which
transcription factors and co-regulators are speci¢cally targeted
by p23 in concert with Hsp90.
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